Targeting Signaling to YAP for the Therapy of NF2
Technical Report,30 Sep 2014,29 Sep 2015
Memorial Sloan Kettering Cancer Center New York United States
Pagination or Media Count:
The goals of this Application are to utilize our new knowledge of the mechanism by which loss of Merlin induces tumorigenesis to identify small molecule compounds that block YAPTEAD-dependent transcription by acting at any step of our newly identified pathway, and to test the preclinical efficacy of lead compounds in xenograft models of NF2. During the first year of this grant, we have generated NF2 mutant cell lines expressing two different types of YAP reporters and tested their suitability for high throughput screening.